載入...
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome (CRS) is a CAR-T therapy–related adverse event. To date, clinical trials of different CAR-T products have not been align...
Na minha lista:
| 發表在: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7160283/ https://ncbi.nlm.nih.gov/pubmed/32271899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001304 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|